US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

20.97

-0.2950-1.39%

Volume:304.38K

Turnover:6.42M

Market Cap:3.69B

PE:-16.80

High:21.41

Open:21.31

Low:20.78

Close:21.26

Loading ...

Overview Company News Filings

Press Release: OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

QNX Announces Free Online Training Courses to Grow and Empower Global Developer Community

ACCESS Newswire

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

QNX Extends Collaboration with AMD to Boost Performance in Robotic Systems

ACCESS Newswire

Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":20.965,"timestamp":1746033079349,"preClose":21.26,"halted":0,"volume":304382,"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Trading","change":-0.295,"latestTime":"04-30 13:11:27 EDT","open":21.31,"high":21.405,"low":20.775,"amount":6416976.453888,"amplitude":0.029633,"askPrice":21,"askSize":6,"bidPrice":20.95,"bidSize":39,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.26,"preHourTrading":{"tag":"盘前","latestPrice":21.25,"preClose":21.26,"latestTime":"09:29 EDT","volume":215,"amount":4575.579905,"timestamp":1746019799999},"postHourTrading":{"tag":"盘后","latestPrice":21.16,"preClose":21.26,"latestTime":"16:07 EDT","volume":7055,"amount":149947.28,"timestamp":1745957229565},"volumeRatio":0.735074,"impliedVol":0.9826,"impliedVolPercentile":0.9788},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":0.735074,"shares":176023203,"dividePrice":0,"high":21.405,"amplitude":0.029633,"preClose":21.26,"low":20.775,"week52Low":16.6942,"pbRate":"9.56","psRate":"7.54","week52High":35.39,"institutionHeld":0,"latestPrice":20.965,"committee":0.733333,"eps":-1.247698,"divideRate":0,"volume":304382,"delay":0,"ttmEps":-1.247698,"open":21.31,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.34,"prevQuarterClose":21.34,"fiveDayClose":20.21,"twentyDayClose":22.68,"sixtyDayClose":28.585,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520931134","title":"Press Release: OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931134?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:05","pubTimestamp":1742328300,"startTime":"0","endTime":"0","summary":"Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today. OmniAb, Inc.  today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates.\"2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach,\" said Matt Foehr, Chief Executive Officer of OmniAb. \"We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our commitment to innovation is a significant competitive advantage and creates exciting opportunities for future growth. We remain steadfast in our strategic direction and are excited about the prospects that lie ahead.\". Net loss for the fourth quarter of 2024 was $13.1 million, or $0.12 per share, compared with a net ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4195","BK4555","BK4121","TM","OS","PFS","GD","BK4211","BK4187","BK4516","BK4566","BK4097","BK4588","BK4232","BK4022","LU0170899867.USD","BK4604","OABI","BK4585","R","BK4550","03160"],"gpt_icon":0},{"id":"2520767842","title":"QNX Announces Free Online Training Courses to Grow and Empower Global Developer Community","url":"https://stock-news.laohu8.com/highlight/detail?id=2520767842","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520767842?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:56","pubTimestamp":1742298960,"startTime":"0","endTime":"0","summary":"Training now available to all in a move that reinforces QNX's commitment to developer success and industry innovation. WATERLOO, ON / ACCESS Newswire / March 18, 2025 / QNX, a division of BlackBerry Limited  today announced the launch of its free QNX Online Training. Consisting of three foundational courses totaling 40 hours of in-depth instruction, the training covers topics such as real-time programming, developing and debugging, and system profiling and analysis.The initiative underscores QNX's continued efforts to foster a skilled global developer community equipped with the tools necessary for success developing and building embedded products for the QNX Operating System , and complements the recently launched QNX Everywhere initiative, which has opened up the business' high performance foundational software for non-commercial use with a view to advancing embedded systems learning, experimentation and innovation. The courses will be updated with new content and features planned to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnx-announces-free-online-training-115600983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BB","BK4547","EMPW.U","BK4097","OS"],"gpt_icon":0},{"id":"2520443526","title":"Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443526","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443526?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:50","pubTimestamp":1742215800,"startTime":"0","endTime":"0","summary":"- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy. - Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment. - Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial. 52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy. Actimab-A + CLAG-M produced high rates of measurable residual disease negativity  including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy. Dr. Sameem Abedin, Associate Professor of Medicine at the Medical College of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4192","NCI","OS","BK4139","MCW","BK4202","ATNM","BK4539","BK4161","HMA","CR","BK4535","BK4097"],"gpt_icon":0},{"id":"2520522383","title":"INAB: Introducing INB-600, A γδ T Cell Engager Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522383","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522383?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:31","pubTimestamp":1742203860,"startTime":"0","endTime":"0","summary":"Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc.  reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme  and acute myeloid leukemia  efforts and presentations at multiple investor and scientific conferences.The most important information shared related to the INB-100 patients. Trial data was updated by about four months from early August 2024 to January 17th, 2025 and were presented at the Transplantation & Cellular Therapy  Meetings in February. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of both progression free survival  and overall survival .General & administrative expenses were $12.6 million, falling 6.5% from $13.5 million. The decrease was pri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-introducing-inb-600-t-093100072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","BK4195","OS","CR","IE00B66KJ199.SGD","BK4097","LU2065731478.USD","PFS","BK4211","INB","IE0031619046.USD","IE00B7SZL793.SGD","CRS","BK4161","BK4539","BK4139","INAB","BK4006"],"gpt_icon":0},{"id":"2519313450","title":"ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2519313450","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519313450?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:00","pubTimestamp":1742040000,"startTime":"0","endTime":"0","summary":"Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer . Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology  Annual Meeting on Women's Cancer in Seattle. \"Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. The data presented today reinforce the importance of ELAHERE as a transformative therapy for patients with limited options,\" said Svetlana Kobina, MD, PhD, vice president, oncology medical affairs, AbbVie. \"We remain steadfast in our commitment to bring forward innovative therapies that improve the lives of patients with difficult-to-treat cancers.\". In the United States, ovarian cancer is the leading cause of death from gynecological cancers.3 Each year, approximately 20,000 women","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948541.HKD","LU1989771016.USD","LU2237443895.HKD","LU1989772840.SGD","LU1934455277.USD","LU0738911758.USD","LU0795875086.SGD","LU1267930573.SGD","LU1430594728.SGD","BK4585","LU0545039389.USD","ADC","LU0985320562.USD","IE0002141913.USD","LU1983299246.USD","LU1037948897.HKD","LU2089984988.USD","LU2237443978.SGD","OS","ABBV","BK4581","LU0965508806.USD","LU0820561818.USD","BK4533","LU1496350502.SGD","LU1244550577.SGD","LU2237443465.HKD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1244550494.USD","SG9999015952.SGD","SG9999015986.USD","LU1291159041.SGD","LU1732799900.SGD","PROC","BK4550","LU0320765646.SGD","PFS","LU0708994859.HKD","BK4080","LU0170899867.USD","LU0417517546.SGD","LU1244550221.USD","ORR","LU2089283258.USD","LU1162221912.USD","BK4195","IE00BVYPNV92.GBP","LU1003077747.HKD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2519838093","title":"OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519838093","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519838093?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:40","pubTimestamp":1741866000,"startTime":"0","endTime":"0","summary":"NEW YORK, March 13, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company’s Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma. This data will be compared with a newly created regulatorily compliant synthetic control group comprised of case matched controls that will be used for the Company’s US Food & Drug Administration  OST-HER2 Biologics License Application  submission. Equivalent submissions with international regulatory authorities will be made in order to gain commercial marketing authorization. MIB Agents FACTOR is the most important annual osteosarcoma conference bringing together the leading osteosarcoma researchers, clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-awarded-ost-her2-114000281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","DC","BK4097","OST","OSTX","BK4017","OS","ADC","BK4231","BK4139","BK4148"],"gpt_icon":0},{"id":"2518418748","title":"OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2518418748","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518418748?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:40","pubTimestamp":1741693200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 11, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting  in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway  with the United Kingdom’s  Medicines and Healthcare products Regulatory Agency  for OST-HER2, its immunotherapy candidate for the prevention of recurrence of metastases in osteosarcoma. The Company released positive Phase 2b data in January 2025 that demonstrates statistically significant results in the primary endpoint of the study, 12-month event free survival . The meeting with MHRA has been scheduled to position the Company to bring OST-HER2 to market in the UK in 2025.\"Today’s announcement marks the beginning of the regulatory process required to bring our OST-HER2 immunotherapy to market globally,\" stated OS Therapies’ CEO Paul Romness. \"As we prepare for regulatory in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-schedules-united-kingdom-114000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UBCP","OSTX","BK4588","BK4528","BK4231","HCSG","BK4158","BK4148","ADC","UK","BK4080","BK4137","BK4139","BK4205","BK4211","MDCO","OST","OS","BK4097","BK4532","BK4233","BK4585","BK4017","SAM","DC"],"gpt_icon":0},{"id":"2518795556","title":"QNX Extends Collaboration with AMD to Boost Performance in Robotic Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2518795556","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518795556?lang=en_us&edition=fundamental","pubTime":"2025-03-11 16:00","pubTimestamp":1741680000,"startTime":"0","endTime":"0","summary":"New QNX Board Support Packages for AMD Adaptive Compute Devices to Enhance the Next Generation of High-Performance Applications. Building on the collaboration announced in April 2024, QNX and AMD continue to push the boundaries of innovation in embedded systems. The enhanced support for AMD devices underscores QNX's commitment to providing robust solutions for industrial, medical, automotive, and robotic workloads, leveraging the real-time operating system  capabilities of QNX to enable systems to operate within strict timing constraints, crucial for embedded software.QNX's initiative to expand support for AMD devices reflects its commitment to offering developers a range of powerful solutions, fostering a diverse and competitive landscape in embedded systems. QNX uses an abstraction layer of hardware-specific software to facilitate the implementation of QNX software on a chosen development platform. It provides initializations and other architecture and hardware-specific tasks needed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnx-extends-collaboration-amd-boost-080000005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2458330169.SGD","BK4547","LU0823421333.USD","BB","IE00BMPRXN33.USD","LU0109392836.USD","SDP","LU0979878070.USD","LU0056508442.USD","LU1242518857.USD","LU1316542783.SGD","LU2360106780.USD","LU2264538146.SGD","LU1064131342.USD","BK4532","LU1880398471.USD","LU1951200564.SGD","BK4588","LU1852331112.SGD","IE00B5949003.HKD","LU0823434740.USD","BK4605","OS","BK4585","LU0889565833.HKD","LU0198837287.USD","BK4543","IE0009356076.USD","LU1303367103.USD","LU2250418816.HKD","LU0719512351.SGD","LU0390134368.USD","LU0823434583.USD","LU0127658192.USD","LU0823421416.USD","BK4614","BK4097","LU2054465674.USD","BK4575","BK4529","LU0082616367.USD","IE0004445239.USD","BK4534","BK4554","GFS","BK4141","BK4612","LU1803068979.SGD","AMD","BK4512"],"gpt_icon":1},{"id":"2518817229","title":"Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518817229","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518817229?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:57","pubTimestamp":1741611420,"startTime":"0","endTime":"0","summary":"Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers. CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase. NT219 headed into Phase 2 head and neck cancer study in combination with pembrolizumab  and in combination with cetuximab . \"We believe that our CAPTN-3 platform is well-positioned and differentiated in the T cell engagers  and multi-specific space, uniquely unleashes both innate and adaptive immune cells against the tumor, demonstrating synergistic effect of the T cell and NK cell activating arms. The unique NKG2A arm in the lead compound acts as a checkpoint inhibitor, enabling simultaneous NK and T cell activation, including effector subsets with high antitumor activity. We are excited about our CAPTN-3 collaboration with the Icahn School of Medicine at Mount Sinai. Our cash runway is expected","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4195","ORR","BK4097","BK4007","BK4211","PFS","PPBT"],"gpt_icon":0},{"id":"2517388304","title":"AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517388304","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517388304?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:54","pubTimestamp":1741352061,"startTime":"0","endTime":"0","summary":"On Friday, AstraZeneca Plc  released high-level results from the MATTERHORN Phase 3 trial evaluatingImfinzi as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal junction  cancers.The trial showed that perioperative treatment with Imfinziin combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival .Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal junction  cancers.A strong trend was observed for the secondary endpoint of overall survival  in favor of theImfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.Gastric cancer is the fifth leading cau","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-based-regimen-shows-125421014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2417539215.USD","BK4568","LU2456880835.USD","BK4588","AZN","LU0320765992.SGD","OS","SSI","LU1829250122.USD","BK4097","BK4585","LU0109394709.USD","LU2462157665.USD","LU2236285917.USD","BK4007","LU0889565916.HKD"],"gpt_icon":0},{"id":"2517482850","title":"Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482850?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:30","pubTimestamp":1741350600,"startTime":"0","endTime":"0","summary":"Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall surv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4202","NCI","LENZ","BK4135","BK4139","OS","BK4097"],"gpt_icon":0},{"id":"2517919484","title":"Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919484","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919484?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Promising Data in Anal Cancer with 33% Response Rate, Including a Durable 15+ Month Complete Response: In the ongoing GOBLET study, Oncolytics' pelareorep combination therapy achieved a 33% objective response rate , including a complete response lasting over 15 months, in twelve evaluable patients with second-line or later unresectable squamous cell carcinoma of the anal canal treated with pelareorep and atezolizumab . This encouraging signal in a very tough-to-treat disease further supports pelareorep's potential in solid tumors. The success criteria in Stage 1 of this Simon two-stage design were previously met; enrollment into Stage 2 of this cohort has begun and will add 18 additional","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BK4097","PFS","OS","BK4195","ONCY","BK4211","BK4139"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","ALK","BK4532","LU2456880835.USD","LU0109394709.USD","BK4006","BK4156","HSCT","BK4588","AZN","LU0320765992.SGD","BK4132","OS","LU2462157665.USD","BK4097","BK4213","BK4124","FLOT","BTC","BK4500","BK4008","VOD","BK4585","TEN","BK4582","LU2236285917.USD","BK4007","LU0889565916.HKD","LU2417539215.USD","BK4144","LU1829250122.USD","CRT","HCC"],"gpt_icon":0},{"id":"2517481546","title":"Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481546?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing. SAN DIEGO and CALGARY, AB, March 7, 2025 /PRNewswire/ -- Oncolytics Biotech  Inc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advancing toward registrational studies that could redefine treatment landscapes in multiple high-need indications. All dollar amounts are expressed in Canadian currency unless otherwise noted.GOBLET gastrointestinal cancer data continue to demonstrate pelareorep's potential across multiple indications. Oncolytics presented t","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ORR","BK4097","BK4232","PFS","OS","BK4195","ONCY","R","BK4211","BK4139"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868837300.USD","HCC","BK4213","LU1032466523.USD","RCC","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","BK4132","BK4581","CRC","LU0096364046.USD","HSCT","BK4157","BK4097","LU0321505868.SGD","LU1868836591.USD","LU1670710588.SGD","LU1261432733.SGD","IE00B19Z4B17.USD","LU0061475181.USD","EC","BMY","LU0237698245.USD","LU1430594728.SGD","LU0306806265.USD","MYE","LU1291159041.SGD","TEN","LU2125154935.USD","ORR","LU0225284248.USD","LU1670711040.USD","LU1868836914.USD","LU1868837136.USD","BK4532","BK4124","LU0306807586.USD","VOD","LU1571399168.USD","OS","CRT","LU0321505439.SGD","IE00B7SZL793.SGD","AEIS","BK4201","LU2242646821.SGD","ALK","LU0114720955.EUR","LU0868494617.USD"],"gpt_icon":0},{"id":"2517132956","title":"HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2517132956","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517132956?lang=en_us&edition=fundamental","pubTime":"2025-03-06 18:00","pubTimestamp":1741255200,"startTime":"0","endTime":"0","summary":"The first patient received the first dose in March 2023 and HUTCHMED expects to announce topline results from the study around the end of 2025. If favorable, the results could enable a New Drug Application submission to China’s National Medical Products Administration .Fanregratinib  is a novel, highly selective and potent inhibitor targeting FGFR 1, 2and3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings.HUTCHMED currently retain all rights to fanregratinib worldwide.This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-announces-completed-enrollment-phase-100000900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4195","BK4007","OS","PFS","BK4211","ORR","HCM","BK4531","BK4588","BK4585"],"gpt_icon":0},{"id":"2517978922","title":"Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978922","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978922?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:00","pubTimestamp":1741215600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, March 05, 2025  -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation  by the Center for Drug Evaluation  of China’s National Medical Products Administration , for combination with low-intensity chemotherapy for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia .This marks the third BTD granted to olverembatinib in China, with the first BTD granted in March 2021, for the treatment of patients with chronic-phase chronic myeloid leukemia  resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors ; and the second BTD granted in June 2023, for the treatment of patients with succinate dehydrogenase -deficient g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/olverembatinib-granted-breakthrough-therapy-designation-230000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4533","BK4588","LU1699723380.USD","CDE","AAPG","BK4585","OS","BK4017","LU2355687059.USD","BK4097","BK4107","LU1571399168.USD","ALL","LU0985320562.USD"],"gpt_icon":0},{"id":"2516622921","title":"TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622921","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622921?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:00","pubTimestamp":1741086000,"startTime":"0","endTime":"0","summary":"New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemotherapy. SAN MATEO, Calif., March 04, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration  has approved TEVIMBRA , in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma  whose tumors express PD-L1 (≥1).\"The approval of TEVIMBRA in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease,\" said Dr. Nataliya Uboha, Associate Professor, University of Wisconsin, Carbone Cancer Center. \"There is a critical need for effective treatments of ESCC, and TEVIMBRA has been shown to improve outcomes in this patient population","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevimbra-approved-u-first-line-110000996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4107","IE00B19Z4B17.USD","OS","LU0053666078.USD","BK4139","BK4588","BK4157","BK4124","LU0053671581.USD","IE00B66KJ199.SGD","BK4585","IE0031619046.USD","AEIS","ONC","BK4161","IE00B7SZL793.SGD","LU0054578231.USD","ITT","HSCT","L","BK4144","TEN"],"gpt_icon":0},{"id":"2516920633","title":"ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516920633","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516920633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer. DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU. TOKYO & BASKING RIDGE, N.J., March 03, 2025----Positive topline results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU  demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival  compared to ramucirumab and paclitaxel in patients with second-line HER2 positive  unresectable and/or metastatic gastric or gastroesophageal junction  adenocarcinoma.\"We are committed to advancing the care of patients with metastatic gastric cancer and continuing to understand the role of ENHERTU in earlier lines of treatment,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology Hematology R&D, AstraZeneca. \"The results of DESTINY-Gastric04 show that second-line treatment with ENHERTU can extend surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-demonstrated-statistically-significant-clinically-130000294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","DSKYF","OS","PBD","BK4225","DSNKY","HR","BK4203","BK4007","BK4231","BK4080","BK4097"],"gpt_icon":0},{"id":"2516236371","title":"Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2516236371","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516236371?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:46","pubTimestamp":1740753960,"startTime":"0","endTime":"0","summary":"This week, Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants. AstraZeneca’s AZN phase III study on breast cancer candidate, camizestrant, meets its primary endpoint. The FDA granted priority review to a supplemental biologics license application  seeking approval for expanded use of Merck’s MRK blockbuster drug, Keytruda, in head and neck squamous cell carcinoma .Here's a recap of the week’s most important stories.LLY to Invest $27B to Expand U.S. Manufacturing Sites. The study’s key secondary endpoints were time to second disease progression  and overall survival . The secondary endpoints were immature at the time of this interim analysis. However, an improving trend in PFS2 was observed for the camizestrant combination arm. The study will continue to assess the secondary endpoints.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-lly-ups-144600821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","LU1868837300.USD","LU0256863902.USD","LU1064131342.USD","LU1035775433.USD","LLY","LU2357305700.SGD","LU2468319806.SGD","SG9999001176.USD","LU0820561818.USD","LU1814569148.SGD","LU0096364046.USD","LU2361044949.HKD","LU2461242641.AUD","BK4516","LU0198837287.USD","LU0094547139.USD","LU0965509101.SGD","LU1366192091.USD","AZN","LU2324357040.USD","LU0672654240.SGD","LU1585245621.USD","LU1430594728.SGD","LU1066051225.USD","SG9999002232.USD","IE00B4R5TH58.HKD","LU1551013425.SGD","LU0320765992.SGD","LU0861579265.USD","LU1267930730.SGD","IE0004445239.USD","LU0203201768.USD","LU0320765489.SGD","MRK","LU1023059063.AUD","LU0471298694.HKD","LU1720051108.HKD","LU1571399168.USD","LU1929549753.HKD","OS","LU2211815571.USD","BK4007","LU0106261372.USD","LU1623119135.USD","LU0203347892.USD","LU0265550946.USD","LU1988902786.USD","LU0114720955.EUR","BK4568"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-29","current":-17.178873,"percent":0.901639,"low":-1655.61542,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"high":-14.493656,"avg":-426.817199,"sd":615.425447,"marketCap":3714089583},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-29","current":-17.178873,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"marketCap":3714089583}],"updateTime":1746033087091}}}